Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Enterprise Value (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Enterprise Value readings, the most recent being -$1.5 billion for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 37.57% to -$1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.5 billion, a 37.57% decrease, with the full-year FY2025 number at -$1.5 billion, down 37.57% from a year prior.
  • Enterprise Value hit -$1.5 billion in Q4 2025 for Neurocrine Biosciences, down from -$1.1 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$648.3 million in Q2 2022 to a low of -$1.5 billion in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$976.2 million (2023), compared with a mean of -$971.1 million.
  • Biggest five-year swings in Enterprise Value: increased 26.74% in 2022 and later tumbled 50.66% in 2023.
  • Neurocrine Biosciences' Enterprise Value stood at -$714.5 million in 2021, then plummeted by 39.55% to -$997.1 million in 2022, then fell by 4.26% to -$1.0 billion in 2023, then fell by 3.51% to -$1.1 billion in 2024, then plummeted by 37.57% to -$1.5 billion in 2025.
  • The last three reported values for Enterprise Value were -$1.5 billion (Q4 2025), -$1.1 billion (Q3 2025), and -$975.6 million (Q2 2025) per Business Quant data.